Recent Finacing
Recent Raise
Aglaia develops small‑molecule inhibitors of mRNA translation initiation to overcome resistance to targeted cancer therapies, advancing a Pierre Fabre–sourced pipeline with Institut Curie, Gustave Roussy and Univ. of Strasbourg.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
